|
|
Résultats pour
brevets
1.
|
Detection and treatment of daughter number variations in cancer cells
| Numéro d'application |
17495768 |
| Numéro de brevet |
11952593 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2021-10-06 |
| Date de la première publication |
2022-04-07 |
| Date d'octroi |
2024-04-09 |
| Propriétaire |
PHARMACOGENETICS LIMITED (Chine)
|
| Inventeur(s) |
Xue, Hong
|
Abrégé
The present disclosure provides in vitro methods for predicting a compound's ability to inhibit multinucleate cell production resulting from post-mitotic cell fusion during a process of Daughter Number Variation (DNV) in mitosis. Compounds identified by this method can be used in cancer treatment, either alone or in combination with other known cancer drugs. The present invention also provides methods of personalized cancer treatment for a patient having a malignant tumor.
Classes IPC ?
- C12N 5/09 - Cellules tumorales
- C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
- G01N 21/64 - FluorescencePhosphorescence
- G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
|
2.
|
GENOME-WIDE CAPTURE OF INTER-TRANSPOSABLE ELEMENT SEGMENTS FOR GENOMIC SEQUENCE ANALYSIS OF HUMAN DNA SAMPLES WITH MICROBIAL CONTAMINATION
| Numéro d'application |
IB2018053534 |
| Numéro de publication |
2018/211477 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2018-05-18 |
| Date de publication |
2018-11-22 |
| Propriétaire |
PHARMACOGENETICS LIMITED (Chine)
|
| Inventeur(s) |
Xue, Hong
|
Abrégé
A method for identifying one or more genomic variations in human genomic DNA, comprising employment of Alu, MIR and SVA sequence-based PCR primers and performing an inter-transposable-element (ITE) polymerase chain reaction on the assay mixture to produce an array of amplicons comprising the ITE genomic segments. Also provided the use of the method for identifying one or more genomic variants associated with a trait or a disease.
Classes IPC ?
- C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
- C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
|
3.
|
COMPOSITIONS OF MEDICINAL PLANTS FOR REDUCING THE EFFECTS OF AGING, PREVENTION AND TREATMENT OF AGE-RELATED NEURODEGENERATIVE DISEASES, AND TREATMENT OF ANXIETY AND SLEEP DISORDERS
| Numéro d'application |
IB2017055279 |
| Numéro de publication |
2018/042384 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2017-09-01 |
| Date de publication |
2018-03-08 |
| Propriétaire |
PHARMACOGENETICS LIMITED (Chine)
|
| Inventeur(s) |
Xue, Hong
|
Abrégé
Compositions comprising extracts prepared from mixtures of the herbal plants Radix Bupleurum chinense DC ("B"), Rhizoma Corydalis yanhusuo WT Wang ("Y"), Caulis Polygonum multiflorum Thunb ("P") and Flos Albizia julibrissin Durazz ("A") are provided. The BYP, BYA, BPA, BY, BP, YP and BYPA extracts significantly decreased one or more of the effects of accelerated aging in mice exposed to D-galactose, including spatial memory deficit, and elevated oxidative stress marker malondialdehyde and pro-inflammatory cytokines TNF-alpha and IL-6 in the brain, indicating efficacy in reducing the damage of aging, and preventing and treating Alzheimer's disease and/or Parkinson's disease. Anxiolysis by the BYA, BPA, YPA, BA and PA extracts indicates efficacy for treating anxiety disorders, and the sedative effect of the BYA, YPA and PA extracts indicates efficacy for treating sleep disorders. None of the extracts significantly induced alteration in locomotor activity, decreased muscle coordination, or anterograde amnesia at the maximum oral dose tested.
|
4.
|
USE OF RECURRENT COPY NUMBER VARIATIONS IN CONSTITUTIONAL HUMAN GENOME FOR PREDICTION OF PREDISPOSITION TO CANCER
| Numéro d'application |
CN2015074606 |
| Numéro de publication |
2015/139652 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2015-03-19 |
| Date de publication |
2015-09-24 |
| Propriétaire |
PHARMACOGENETICS LIMITED (Chine)
|
| Inventeur(s) |
- Xue, Hong
- Ding, Xiaofan
- Tsang, Shui-Ying
|
Abrégé
In the present application, prediction on the predisposition of a human test subject to cancer is made based on machine learning-assisted comparison of the copy number variations ("CNV") found in the constitutional DNA of the test subject with a set of diagnostic recurrent CNV features (viz. markers) selected from a collection of constitutional DNA samples from noncancer subjects (designated as "Noncancer DNA" samples) plus constitutional DNA samples from cancer patients (designated as "Cancer DNA" samples), all from the same ethnic group as the test subject. Selection and testing of the set of diagnostic recurrent CNV features is performed using a machine learning procedure, exemplified by the CFS-based method, the Frequency-based method and the Classifier-based method, together with the Naive Bayes classification method. Prediction of the test subject's predisposition to cancer is also performed with the Naive Bayes classification method. The cancer patients from whom the constitutional "Cancer DNA" samples are prepared, for the purpose of selection of the diagnostic recurrent CNV features, can consist of patients inflicted with one type of cancer or more than one types of cancers.
Classes IPC ?
- C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
|
|